Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases

British Journal of Pharmacology

Volumn 162, Issue 4, 2011, Pages 989-999

  Illingworth, N A ^a   Boddy, A V ^a   Daly, A K ^b   Veal, G J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

CYP2C8; cytochrome P450; fenretinide; metabolism; microsomes; UDP glucuronosyltransferases

Indexed keywords

4' HYDROXYFENRETINIDE; 4' OXOFENRETINIDE; CYTOCHROME P450; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; CYTOCHROME P450 INHIBITOR; DRUG METABOLITE; FENRETINIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A3; GLUCURONOSYLTRANSFERASE 1A6; UNCLASSIFIED DRUG;

AEROBIC METABOLISM; ARTICLE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ANALYSIS; HUMAN; HUMAN CELL; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN METHYLATION;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; FENRETINIDE; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; INTESTINES; KINETICS; MICROSOMES; MICROSOMES, LIVER; MUTANT PROTEINS; RECOMBINANT PROTEINS; TRETINOIN;

EID: 79251518085     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.01104.x     Document Type: Article

References (37)

1. Ansher SS, Jakoby WB, (1986). Amine N-methyltransferases from rabbit liver. J Biol Chem 261: 3996-4001.
2. Armstrong JL, Ruiz M, Boddy AV, Redfern CPF, Pearson ADJ, Veal GJ, (2005). Increasing the intracellular availability of all-trans retinoic acid in neuroblastoma cells. Br J Cancer 92: 696-704.
3. Armstrong JL, Taylor GA, Thomas HD, Boddy AV, Redfern CPF, Veal GJ, (2007). Molecular targeting of retinoic acid metabolism in neuroblastoma: the role of the CYP26 inhibitor R116010 in vitro and in vivo. Br J Cancer 96: 1675-1683.
4. Bahadur N, Leathart JBS, Mutch E, Steimel-Crespi D, Dunn SA, Gilissen R, et al. (2002). CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6α-hydroxylase activity in human liver microsomes. Biochem Pharmacol 64: 1579-1589.
5. Czernik PJ, Little JM, Barone GW, Raufman JP, Radominska-Pandya A, (2000). Glucuronidation of estrogens and retinoic acid and expression of UDP-glucuronosyltransferase 2B7 in human intestinal mucosa. Drug Metab Dispos 28: 1210-1216.
6. Dai D, Zeldin DC, Blaisdell JA, Chanas B, Coulter SJ, Ghanayem BI, et al. (2001). Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics 11: 597-607.
7. Formelli F, Carsana R, Costa A, Buranelli F, Campa T, Dossena G, (1989). Plasma retinol level reduction by the synthetic retinoid fenretinide: a one year follow-up study of breast cancer patients. Cancer Res 49: 6149-6152.
8. Formelli F, Clerici M, Campa T, Di Mauro MG, Magni A, Mascotti G, et al. (1993). Five-year administration of fenretinide: pharmacokinetics and effects on plasma retinol concentrations. J Clin Oncol 11: 2036-2042.
9. Formelli F, Cavadini E, Luksch R, Garaventa A, Villani MG, Appierto V, et al. (2008). Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide. Cancer Chemother Pharmacol 62: 655-665.
10. Garaventa A, Luksch R, Piccolo MSL, Cavadini E, Montaldo PG, Pizzitola MR, et al. (2003). Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. Clin Cancer Res 9: 2032-2039.
11. Gatta G, Capocaccia R, Coleman MP, Gloeckler LA, Berrino F, (2002). Childhood cancer survival in Europe and the United States. Cancer 95: 1767-1772.
12. Hultin TA, Filla MS, McCormick DL, (1990). Distribution and metabolism of the retinoid N-(4-Methoxyphenyl)-all-trans-retinamide, the major metabolite of N-(4-Hydroxyphenyl)-all-trans-Retinamide, in female mice. Drug Metab Dispos 18: 175-179.
13. Huynh CK, Brodie AMH, Njar VCO, (2006). Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. Br J Cancer 94: 513-523.
14. Kitareewan S, Spinella MJ, Allopenna J, Reczek PR, Dmitrovsky E, (1999). 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RAR independent pathway. Oncogene 18: 5747-5755.
15. Li X-Q, Andersson TB, Ahlström M, Weidolf L, (2004). Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 32: 821-827.
16. Lovat PE, Ranalli M, Annichiarrico-Petruzzelli M, Bernassola F, Piacentini M, Malcolm AJ, et al. (2000). Effector mechanisms of fenretinide-induced apoptosis in neuroblastoma. Exp Cell Res 260: 50-60.
17. McSorley LC, Daly AK, (2000). Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochem Pharmacol 60: 517-526.
18. Marachelian A, Kang MH, Hwang K, Villablanca JG, Groshen S, Matthay KK, et al. (2009). Phase I study of fenretinide (4-HPR) oral powder in patients with recurrent or resistant neuroblastoma: New Approaches to Neuroblastoma Therapy (NANT) Consortium trial. J Clin Oncol 27 (15S): 10009.
19. Marill J, Cresteil T, Lanotte M, Chabot G, (2000). Identification of human cytochrome P450s involved in the formation of all-trans-retinoic acid principal metabolites. Mol Pharmacol 58: 1341-1348.
20. Marill J, Capron CC, Idres N, Chabot GG, (2002). Human cytochrome P450s involved in the metabolism of 9-cis- and 13-cis-retinoic acids. Biochem Pharmacol 63: 933-943.
21. Maurer BJ, Kalous O, Yesair DW, Wu X, Janeba J, Maldonado V, et al. (2007). Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a Novel LYM-X-SORB organized lipid complex. Clin Cancer Res 13: 3079-3086.
22. Mehta RR, Hawthorne ME, Graves JM, Mehta RG, (1998). Metabolism of N-[4-hydroxyphenyl]retinamide (4-HPR) to N-[4-methoxyphenyl]retinamide (4-MPR) may serve as a biomarker for its efficacy against human breast cancer and melanoma cells. Eur J Cancer 34: 902-907.
23. Myatt SS, Burchill SA, (2007). The sensitivity of the Ewing's sarcoma family of tumours to fenretinide-induced cell death is increased by EWS-Fli1-dependent modulation of p38MAPK activity. Oncogene 27: 985-986.
24. Njar VCO, Gediya L, Purushottamachar P, Chopra P, Vasaitis TS, Khandelwal A, et al. (2006). Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 14: 4323-4340.
25. Ong C-E, Coulter S, Birkett DJ, Bhasker CR, Miners JO, (2000). The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 50: 573-580.
26. Ponthan F, Lindskog M, Karnehed N, Castro J, Kogner P, (2003). Evaluation of anti-tumour effects of oral fenretinide (4-HPR) in rats with human neuroblastoma xenografts. Oncol Rep 10: 1587-1592.
27. Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV, (2010a). Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans. Drug Metab Dispos 38: 1211-1217.
28. Rowbotham SE, Boddy AV, Redfern CPF, Veal GJ, Daly AK, (2010b). Relevance of non-synonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation. Drug Metab Dispos 38: 1261-1266.
29. Samokyszyn VM, Gall WE, Zawada G, Freyaldenhoven MA, Chen G, Mackenzie PI, et al. (2000). 4-hydroxyretinoic acid, a novel substrate for human liver microsomal UDP-glucuronosyltransferase(s) and recombinant UGT2B7. J Biol Chem 275: 6908-6914.
30. Schwartz EL, Hallam S, Gallagher RE, Wiernik PH, (1995). Inhibition of all-trans-retinoic acid metabolism by fluconazole in vitro and in patients with acute promyelocytic leukemia. Biochem Pharmacol 50: 923-928.
31. Smith HE, Jones JP, Kalhorn TF, Farin FM, Stapleton PL, Davis CL, et al. (2008). Role of cytochrome P450 2C8 and 2J2 genotypes in calcineurin inhibitor-induced chronic kidney disease. Pharmacogenet Genomics 18: 943-953.
32. Swanson BN, Zaharevitz DW, Sporn MB, (1980). Pharmacokinetics of N-(4-hydroxyphenyl)-all-trans-retinamide in rats. Drug Metab Dispos 8: 168-172.
33. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP, (2006). Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol 24: 3423-3430.
34. Villani MG, Appierto V, Cavadini E, Valsecchi M, Sonnino S, Curley RW, et al. (2004). Identification of the fenretinide metabolite 4-oxo-fenretinide present in human plasma and formed in human ovarian carcinoma cells through induction of cytochrome P450 26A1. Clin Cancer Res 10: 6265-6275.
35. Villani MG, Appierto V, Cavadini E, Bettiga A, Prinetti A, Clagett-Dame M, et al. (2006). 4-oxo-fenretinide, a recently identified fenretinide metabolite, induces marked G2-M cell cycle arrest and apoptosis in fenretinide-sensitive and fenretinide-resistant cell lines. Cancer Res 66: 3238-3247.
36. Vratilova J, Frgala T, Maurer BJ, Reynolds PC, (2004). Liquid chromatography method for quantifying N-(4-hydroxyphenyl)retinamide and N-(4-methoxyphenyl)retinamide in tissues. J Chrom B 808: 125-130.
37. Zhang Q, Dunbar D, Kaminsky L, (2000). Human cytochrome P-450 metabolism of retinals to retinoic acids. Drug Metab Dispos 28: 292-297.